Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Depreciation and Depletion (2016 - 2020)

Champions Oncology has reported Depreciation and Depletion over the past 11 years, most recently at $254000.0 for Q4 2020.

  • For Q4 2020, Depreciation and Depletion rose 56.79% year-over-year to $254000.0; the TTM value through Oct 2020 reached $295000.0, up 49.75%, while the annual FY2025 figure was $150000.0, 2.74% up from the prior year.
  • Depreciation and Depletion for Q4 2020 was $254000.0 at Champions Oncology, up from $224000.0 in the prior quarter.
  • Over five years, Depreciation and Depletion peaked at $254000.0 in Q4 2020 and troughed at -$367000.0 in Q2 2020.
  • A 5-year average of $63117.6 and a median of $98000.0 in 2018 define the central range for Depreciation and Depletion.
  • Biggest five-year swings in Depreciation and Depletion: surged 208.33% in 2018 and later tumbled 54.85% in 2020.
  • Year by year, Depreciation and Depletion stood at $34000.0 in 2016, then surged by 144.12% to $83000.0 in 2017, then surged by 38.55% to $115000.0 in 2018, then skyrocketed by 40.87% to $162000.0 in 2019, then surged by 56.79% to $254000.0 in 2020.
  • Business Quant data shows Depreciation and Depletion for CSBR at $254000.0 in Q4 2020, $224000.0 in Q3 2020, and -$367000.0 in Q2 2020.